Personalis, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
ARK ETFs made significant trades on October 14, 2026, including buying 188,665 shares of CoreWeave (CRWV) for $14.7M and selling 693,049 shares of Personal Genome (PSNL) for $11M. Other notable transactions involved Meta (META), 10X Genomics (TXG), Toast (TOST), and Cerebras (CBRS).
ARK ETFs bought CoreWeave (CRWV) and Kratos (KTOS) for $19.68M and $9.15M, respectively, and sold Robinhood (HOOD) and Personalis (PSNL) for $17.01M and $12.01M. Other trades included Teradyne (TER), Recursion (RXRX), and smaller positions in several other companies.
Person has agreed to a merger with Tempus, becoming a wholly owned subsidiary. The HSR waiting period expired on Oct 2, 2026. The deal requires stockholder approval and other conditions. Tempus filed relevant documents with the SEC.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning PSNL (Personalis, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent PSNL coverage spans mergers & acquisitions, financial news and market movers.
In the last 30 days, PSNL insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($267K). The most active reporter was Moore Stephen Michael, SVP and Chief Legal Officer, with 1 filing.
Sell signal from a prominent fund.
May weigh on the stock in the near term.
The merger announcement is likely to drive PSNL stock higher as the market prices in the deal completion.
The announced merger could unlock a premium for Personalis shareholders if approved.
Downgrade removes upside and highlights deal‑completion risk, likely pressuring the stock lower.
AlphAI scores every news story that mentions PSNL with an AI model for sentiment and relevance, and aggregates insider trades from Personalis, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ARK ETFs made significant trades on October 14, 2026, including buying 188,665 shares of CoreWeave (CRWV) for $14.7M and selling 693,049 shares of Personal Genome (PSNL) for $11M. Other notable transactions involved Meta (META), 10X Genomics (TXG), Toast (TOST), and Cerebras (CBRS).
2 min readARK ETFs bought CoreWeave (CRWV) and Kratos (KTOS) for $19.68M and $9.15M, respectively, and sold Robinhood (HOOD) and Personalis (PSNL) for $17.01M and $12.01M. Other trades included Teradyne (TER), Recursion (RXRX), and smaller positions in several other companies.
2 min readPerson has agreed to a merger with Tempus, becoming a wholly owned subsidiary. The HSR waiting period expired on Oct 2, 2026. The deal requires stockholder approval and other conditions. Tempus filed relevant documents with the SEC.
1 min readPersonalis, Inc. (PSNL) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on July 20, 2026, Personalis, Inc., a Delaware corporation (“ Personalis ” or the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Tempus AI, Inc., a Nevada corporation (“ Tempus ” or “ Par
2 min readPersonalis (PSNL) stock fell 2.8% after BTIG downgraded it to Neutral, removing the $16.25 price target. The analyst believes the Tempus AI acquisition will close at the agreed price, with little chance of improvement. BTIG also concluded that the board prioritized deal speed over a higher bid, despite interest from Merck. The S&P 500 and other indices rose, but Personalis' decline was stock-specific.
1 min readPersonalis CFO Aaron Tachibana sold 2,931 shares at $16.22 each, totaling $47,540, to cover tax obligations. Tempus AI agreed to acquire Personalis for $1.5B, offering $16.25 per share, a 6% premium. Needham downgraded Personalis to Hold, raised its target to $17, and reiterated a Buy rating for Tempus AI with a $75 target. Personalis received UK regulatory clearance for its NeXT Personal Dx test.
2 min readHall Christopher M (Chief Executive Officer) sold 7,459 shares of Personalis, Inc. (PSNL) at $16.22 ($0.12M total) on 2026-09-18.
1 min readModerna and Merck's personalized mRNA cancer vaccine (mRNA-4157) met its primary endpoint in Phase 3 trials, boosting their market value by over $50 billion. The success highlights the role of sequencing companies like Tempus AI and Personalis, which provide genetic profiling for personalized vaccines. Tempus AI's planned acquisition of Personalis faces competition as Personalis' stock surpasses the offer price, sparking speculation of a bidding war. The deal's strategic value lies in Personalis
4 min readPersonalis (PSNL) received a new $18.3M task order from the U.S. Department of Veterans Affairs, bringing its cumulative VA MVP task orders to $243.3M. The stock has seen significant gains, with a 30-day return of 42.57% and a year-to-date gain of 117.58%. Analysts estimate a fair value of $15.44 per share, suggesting the stock is overvalued at its last close of $17.08. Investors should consider risks such as delayed reimbursements and potential underperformance of large contracts.
2 min readPersonalis (PSNL) stock rose 24.0% after securing a new $18.3M task order from the U.S. Department of Veterans Affairs' Million Veteran Program, bringing its total VA MVP contracts to $243.3M. The company projects $168.4M revenue and $27.7M earnings by 2029, despite ongoing losses. Tempus' pending acquisition of Personalis for $1.6B highlights its value in genomics and MRD capabilities.
2 min read
